Novel multimeric IL-1 receptor antagonist for the treatment of rheumatoid arthritis. (February 2015)

• Record Type: Journal Article
• Authors: Pasi, Shweta; Kant, Ravi; Gupta, Sarika; Surolia, Avadhesha
• Is Part Of: Biomaterials. Volume 42(2015)
• Page Start: 121
• Page End: 133
• Publication Date: 2015-02
• Subjects: IL-1 receptor antagonist -- Multimeric -- Rheumatoid arthritis -- Anakinra; Biomedical materials -- Periodicals; Biocompatible Materials -- Periodicals; Biomatériaux -- Périodiques; 610.28
• DOI: 10.1016/j.biomaterials.2014.11.041
• Languages: English
• ISSNs: 0142-9612

Abstract

Abstract: Protein therapeutics targeting inflammatory mediators have shown great promise for the treatment of autoimmunities such as rheumatoid arthritis (RA). However, a significant challenge in this area has been their low in vivo stability and consequently their severely compromised therapeutic efficacy. One such therapeutic molecule IL-1 receptor antagonist (IL-1ra), used in the treatment of rheumatoid arthritis, has displayed only modest efficacy in human clinical trials owing to its short biological half-life. Herein, we report a novel approach to conglomerate individual protein entities into a drug depot by incorporation of an amyloidogenic motif Lys-Phe-Phe-Glu (KFFE) thereby dramatically improving their systemic persistence and in turn their therapeutic efficacy in a mice model of autoimmune arthritis.